Meeting
2022 ASCO Annual Meeting
Phase III study with atezolizumab versus placebo in patients with malignant pleural mesothelioma after pleurectomy/decortication (AtezoMeso study).
Authors
Maria Pagano
Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Maria Pagano , Marco Alloisio , Federico Cappuzzo , Francesco Facciolo , Paolo Bironzo , Ugo Pastorino , Federico Rea , Armando Santoro , Francesca Zanelli , Giulia Alberti , Candida Bonelli , Erika Gervasi , Carmine Pinto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
2020-003762-39; GOIRC-02-2019
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8591)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8591
Abstract #
TPS8591
Poster Bd #
216b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu
Poster
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
First Author: Vassiliki Papadimitrakopoulou
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
First Author: Patrick M. Forde